Clinical Trial Update: Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial (NCT06699771) is evaluating the safety, tolerability, and preliminary efficacy of GCC2005. The trial focuses on patients with relapsed/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer T-cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• GCC2005

Snippet

Sponsor: GC Cell Corporation | Conditions: Lymphoma, T-Cell | Phase 1 | Status: RECRUITING